ELARA trial: tisagenlecleucel response extends to 4 years in follicular lymphoma
Researchers presented 4-year follow-up data from the phase 2 ELARA study, showing that response to tisagenlecleucel continues to deepen in patients with follicular
18-IMCL
News
ASCO 2025
Video Interviews
What do the real-world data show on luspatercept in LR-MDS?
In this video interview with Idoroenyi Amanam, MD, an assistant professor in City of Hope’s Division of Leukemia in the Department of Hematology
18-IMCL
News
GOLSEEK-1 phase 3 study of golcadomide for untreated LBCL
Golcadomide, an investigational first-in-class oral CELMoD, is being assessed in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients with high-risk
EHA 2025
B-ALL patients refractory to brexu-cel face poor survival outcomes
Relapse after treatment with the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (brexu-cel) is associated with limited survival outcomes, “underscoring a need
EHA 2025
Pediatric-inspired Ph– ALL protocol reduces toxicity without improving survival
Researchers introduced a pediatric-inspired treatment protocol at their institution for patients with Philadelphia-negative (Ph–) acute lymphoblastic leukemia (ALL) and found that overall survival
Lymphoma
Indolent B-Cell Lymphomas
News
FDA approves tafasitamab combo therapy for relapsed or refractory follicular lymphoma
The US Food and Drug Administration (FDA) has approved tafasitamab-cxix, a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide
EHA 2025
Post-CAR-T recovery of T cell, NK cell counts predicts long-term prognosis in B-ALL
Early recovery of specific T-cell counts and natural killer (NK) cell counts after CD19 chimeric antigen receptor (CAR)-T therapy can be used as
EHA 2025
Meetings / Conferences
News
Study supports recommendation that pregnancy be avoided in women taking ponatinib
A small study found that among pregnancies in which the mother was exposed to ponatinib, cases of Hirschsprung’s disease (HD) occurred. Paternal exposure
News
Study finds ropeginterferon alfa-2b is ‘superior’ 2nd-line treatment for essential thrombocythemia
A study compared second-line treatment options for essential thrombocythemia (ET) and found that ropeginterferon alfa-2b “outperformed” anagrelide in both efficacy and safety outcomes.
EHA 2025
Longer-term follow-up demonstrates efficacy of nemtabrutinib for refractory FL
Follow-up results from the BELLWAVE-003 study assessing nemtabrutinib in patients with hematologic malignancies showed continued antitumor activity and no new safety concerns with